{
  "scenario_id": "biotechnology_gene_editing_ethics_decision",
  "context": "Biotechnology company developing CRISPR-based therapies for genetic diseases, facing ethical dilemmas in clinical advancement",
  "stakeholders": {
    "requester": "Chief Scientific Officer",
    "approvers": [
      "CEO",
      "Board of Directors",
      "Ethics Committee"
    ],
    "influencers": [
      "Patient Advocacy Groups",
      "Regulatory Agencies",
      "Scientific Community"
    ]
  },
  "request": {
    "amount": "$50 million",
    "purpose": "Advance gene editing therapy to Phase 1 clinical trials",
    "urgency": "high",
    "justification": "Potential to cure previously untreatable genetic diseases affecting millions"
  },
  "decision_process": [
    {
      "stage": "ethical_review",
      "duration": "4 weeks",
      "activities": [
        "Bioethics consultation",
        "Stakeholder engagement",
        "Risk-benefit analysis"
      ],
      "outcome": "Conditional approval with enhanced oversight requirements"
    },
    {
      "stage": "scientific_validation",
      "duration": "6 weeks",
      "activities": [
        "Peer review",
        "Independent validation studies",
        "Safety data review"
      ],
      "outcome": "Scientific merit confirmed with safety concerns addressed"
    },
    {
      "stage": "regulatory_navigation",
      "duration": "8 weeks",
      "activities": [
        "FDA pre-IND meetings",
        "Regulatory strategy development",
        "Compliance framework establishment"
      ],
      "outcome": "Regulatory pathway clarified with accelerated approval potential"
    }
  ],
  "business_impact": {
    "expected_patients_treated": 10000,
    "projected_revenue": "$2 billion",
    "risk_factors": [
      "Ethical controversies",
      "Regulatory delays",
      "Off-target effects",
      "Public backlash"
    ]
  }
}